News Archive
Remote Access
O365 Access DIAM VDI DIAM Remote Access TAC Remote Access (DMMI, DMAR, DMCN) DMTN VDI DMAT VDI DMTN Remote Access DMAT Remote Access DPAM Remote Access DSCN Remote Access

Quick Links

DENSO North America Website DENSO Presentation Library Oracle Fusion Oracle Fusion Help DENSO Benefits Healthy Horizons Empower Retirement DMTN Associate Resource Center
News Archive
Remote Access
O365 Access DIAM VDI DIAM Remote Access TAC Remote Access (DMMI, DMAR, DMCN) DMTN VDI DMAT VDI DMTN Remote Access DMAT Remote Access DPAM Remote Access DSCN Remote Access

Coronavirus

DENSO continues to monitor the risks of COVID-19 to our associates and operations


Key Documents & Links

  • US Face Mask Policy
  • COVID-19 Record System
  • NA Risk Minimization Toolkit
  • Travel & Visitor Guidelines
  • Business Ethics & Compliance Resources
  • CDC website

Who to Contact

Please contact us if you have any questions or concerns.

North America
COVID-19 Task Force
 
covid@na.denso.com

BCBSM Nurse Helpline
(for BCBSM members only)
tel: 1-800-775-2583  

Back

Share this:

March 29, 2021

DIAM COVID-19 Weekly Case Count & Vaccine Info (March 19-26, 2021)

DENSO International America, Inc.
Weekly COVID-19 Case Update

This week, we learned that four (4) DIAM associates were diagnosed with COVID-19.

  • One associate was last on site at DIAM Southfield DN40 on March 4, and received a positive diagnosis on March 24. 
  • One associate was last on site at DIAM Southfield DN20 and Shipping & Receiving on Feb. 19 and received a positive diagnosis on March 24. 
  • One associate was last visiting the ASKY campus on March 11 and received a positive diagnosis on March 22. They have not been on any DIAM campus recently. 
  • One associate was last on site at DIAM Southfield DN1-4 on March 18, and reported symptoms on March 20.

Following our guidelines, we have thoroughly cleaned and sanitized all areas where these associates had prolonged contact, including the common spaces in all buildings. Everyone who needs to quarantine due to close contact with this associate has been notified. Please respect confidentiality, even if you believe you know who these individuals are.

Screening Survey Required to Come Onsite

All associates are required to complete the COVID-19 Daily Screening Survey prior to every DIAM campus visit. There are 3 ways you can access the survey:

  • Survey Link: www.densomedia-na.com/coronavirus/survey/  (Note: if you are using the Outlook mobile app, you will need to download the Edge browser from the Company Portal in order to view this link). If you go to campus regularly – bookmark this link!
  • DENSO Mobile: Go to densomobile.com and create your account or login. Once you’re on DENSO Mobile, click on the scrolling graphic at the top of the app labeled “COVID-19 Screening Survey”.
  • DENSO Online: Go to densoonline.com and click on the “Coronavirus” section (password: denso2020). Find the survey under “Key Documents & Links”.

If you have COVID-19 Symptoms or Diagnosis:

  • Do not come to any DIAM campus
  • Inform your manager or chain of command
  • You or your manager needs to send an email to covid@na.denso.com with the following details: date symptoms started, date of last day onsite, date of COVID-19 test results
  • Someone will follow up with you to gather additional information

Some symptoms may include: fever, cough, fatigue, shortness of breath, chills, persistent headache, loss of smell or taste. For a complete list of COVID-19 symptoms, visit the CDC website.

 

DENSO International America, Inc.
Weekly COVID-19 Case Update

Although cases at DENSO affiliates in North America continue to flatten, we are seeing a rise in case rates in the communities where we live and work. More associates are choosing to travel and resume some activities while COVID-19 variants are increasing infection rates. This week at DENSO affiliates in North America, 38 positive COVID-19 diagnoses were reported. Throughout Canada, Mexico and the United States (U.S.), DENSO has reported a total of 2,896 total positive diagnoses.

Following local investigations into cases at DENSO facilities this week, all were classified as community spread (household, gatherings, travel, etc.).

Screening Survey Required to Come Onsite

All associates are required to complete the COVID-19 Daily Screening Survey prior to every DIAM campus visit. There are 3 ways you can access the survey:

  • Survey Link: www.densomedia-na.com/coronavirus/survey/  (Note: if you are using the Outlook mobile app, you will need to download the Edge browser from the Company Portal in order to view this link). If you go to campus regularly – bookmark this link!
  • DENSO Mobile: Go to densomobile.com and create your account or login. Once you’re on DENSO Mobile, click on the scrolling graphic at the top of the app labeled “COVID-19 Screening Survey”.
  • DENSO Online: Go to densoonline.com and click on the “Coronavirus” section (password: denso2020). Find the survey under “Key Documents & Links”.

If you have COVID-19 Symptoms or Diagnosis:

  • Do not come to any DIAM campus
  • Inform your manager or chain of command
  • You or your manager needs to send an email to covid@na.denso.com with the following details: date symptoms started, date of last day onsite, date of COVID-19 test results
  • Someone will follow up with you to gather additional information
Country This Week’s Cases Total Positive Diagnosis Number of Deaths Exposed in Community Exposed at DENSO Unable to Determine Under Investigation
US 28 1613 4 1591 14 8 0
MX 8 1275 4 1200 48 27 0
CN 2 8 0 8 0 0 0
NA TOTALS 38 2896 8 2799 62 35 0

 

Exposed in Community – transmission attributed to community or home

Exposed at DENSO – transmission attributed to DENSO site contact

Unable to Determine – cannot confidently determine the source of exposure after thorough investigation (may have been exposed outside or inside of work)

Under Investigation – investigation is on-going both internally as well as with county health departments

Some symptoms may include: fever, cough, fatigue, shortness of breath, chills, persistent headache, loss of smell or taste. For a complete list of COVID-19 symptoms, visit the CDC website.

COVID-19 Vaccine: Is it safe?

Over 126 million doses of COVID-19 vaccine were administered in the United States from December 14, 2020, through March 22, 2021. These vaccines are undergoing the most intensive monitoring in U.S. history to make sure they are safe. COVID-19 vaccines are safe and effective.

Results from monitoring efforts are reassuring. Some people have no side effects. Others have reported common side effects after COVID-19 vaccination like swelling, redness and pain at injection site, fever, headache, tiredness, muscle pain, chills, or nausea. These reactions are common, and go away after a day or two.

As vaccine eligibility and availability expands, please choose to protect yourself and your family from this deadly virus as soon as possible. Find a local vaccine site at www.vaccinefinder.org.

Published by DENSO INTERNATIONAL AMERICA, INC. for associates and friends of DENSO companies, joint ventures and affiliates in North America.

Follow Us

©DENSO INTERNATIONAL AMERICA, INC. 2023 All rights reserved. Ownership and Use

✖